Aeson artificial heart hits 72.7% primary endpoint rate in largest clinical study yet
The EFICAS study of the Aeson Total Artificial Heart achieved its primary endpoint in 72.7% of 55 severely ill patients, with 96% remaining free of disabling stroke at 180 days and 76% discharged from hospital.